Leukemia Partnering in 2007-2012 Reviewed by CurrentPartnering
19 Mar 2012 • by Natalie Aster
Insightful analysis of leukemia partnering deals is the focus of the CurrentPartnering report “Leukemia Partnering 2007-2012”. It provides understanding and access to the leukemia partnering deals and agreements entered into by the world leading healthcare companies.
The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors leukemia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Leukemia Partnering 2007-2012
Published: February, 2012
Price: US$ 995,00
This data driven report contains over 150 links to online copies of actual leukemia deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
More information can be found in the report “Leukemia Partnering 2007-2012” by CurrentPartnering.
To order the report or ask for sample pages contact [email protected]